As numerous publications have linked TRPA1 and TRPV1 with inflammatory pain [21], therapeutic inhibition or the activation of TRPA1 and/or TRPV1 channels may be beneficial in the treatment of DDD. The gene discussed is TRPA1; the disease is Dowling-Degos disease 1.